Compare MNY & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | ECOR |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 52.4M |
| IPO Year | N/A | N/A |
| Metric | MNY | ECOR |
|---|---|---|
| Price | $1.30 | $6.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $22.00 |
| AVG Volume (30 Days) | 47.5K | ★ 71.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | $19.58 | $32.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $4.16 |
| 52 Week High | $2.40 | $19.49 |
| Indicator | MNY | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 51.74 |
| Support Level | $1.26 | $5.15 |
| Resistance Level | $1.31 | $5.73 |
| Average True Range (ATR) | 0.03 | 0.64 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 96.99 | 34.70 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.